Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Chia, Stephen; K. Gandhi, Sanjiv; A. Joy, Anil; Edwards, S.; W. Gorr, Matthew; Hopkins, Sean; Kondejewski, J.; Ayoub, Jean-Pierre; Califaretti, Nadia; Rayson, Daniel; Dent, Susan

doi:10.3747/co.22.2393

Public

Novel Agents and Associated Toxicities of Inhibitors of the PI3K/Akt/mTOR Pathway for the Treatment of Breast Cancer

Published in Current Oncology • Feb 1, 2015

Authors:

Stephen Chia

Sanjiv K. Gandhi

Anil A. Joy

Abstract

UNLABELLED: The pi3k/Akt/mtor (phosphatidylinositol 3 kinase/ Akt/mammalian target of rapamycin) signalling pathway is an established driver of oncogenic activity in human malignancies. Therapeutic targeting of this pathway holds significant promise as a treatment strategy. Everolimus, an mtor inhib...

Subject

PI3K/AKT/mTOR pathway

Everolimus

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!